Medicenna Therapeutics Corp. (MDNA)
Stock Price:
$4.16 USD
0.11 (2.72%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $4.25 +0.09 (2.16%) Oct 23, 5:04 PM
Key Info
| Market Cap |
203.20M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.33M |
| Shares Out |
48.85M |
| EPS (ttm) |
-0.19 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$4.16 |
| Previous Close |
$4.05 |
| Change ($) |
0.11 |
| Change (%) |
2.72% |
| Day's Open |
4.09 |
| Day's Range |
4.07 - 4.23 |
| Day's Volume |
71,109 |
| 52-Week Range |
3.47 - 5.03 |
More Stats
| Market Cap |
203.20M |
| Enterprise Value |
162.63M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
48.85M |
| Float |
32.54M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.19 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
29,639 |
| Short Ratio |
0.66 |
| Short % of Float |
0.09% |
| Beta |
0.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.59 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-9.33M |
| Free Cash Flow |
n/a |
| Net Cash |
40.57M |
| Net Cash / Share |
0.83 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-26.63% |
| ROE |
-45.37% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.53*
(105.05% upside)
Low
6.79
Current: $4.16
High
10.57
Target: 8.53
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -8.24 | -4.73 |
| Net Income | -8.28 | -4.71 |
| Shares Outstanding | 31.90 | 25.67 |
| Earnings Per Share | -0.26 | -0.18 |
| Operating Cash Flow | -8.95 | -8.04 |
| Capital Expenditures | - | -0.35 |
| Free Cash Flow | -8.95 | -8.39 |
| Cash & Equivalents | 37.70 | 2.37 |
| Total Debt | 0.07 | - |
| Net Cash / Debt | 37.63 | 2.37 |
| Assets | 38.00 | 5.19 |
| Liabilities | 1.85 | 2.57 |
| Book Value | 36.15 | 2.62 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Medicenna Therapeutics Corp. |
| Country |
Canada |
| Employees |
7 |
| CEO |
Fahar Merchant |
Stock Information
| Ticker Symbol |
MDNA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: MDNA |
Description
Medicenna Therapeutics, a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.